Explore

Trendline Trendline
KalVista Pharmaceuticals to Present at Needham Virtual Healthcare Conference, Highlighting Rare Disease Treatments

KalVista Pharmaceuticals to Present at Needham Virtual Healthcare Conference, Highlighting Rare Disease Treatments

KalVista Pharmaceuticals to Present at Needham Virtual Healthcare Conference, Highlighting Rare Disease Treatments
Trendline Trendline
Amylyx Pharmaceuticals to Present at Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals to Present at Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals to Present at Needham Virtual Healthcare Conference
Trendline Trendline
Amylyx Pharmaceuticals to Present at Needham Virtual Healthcare Conference Highlighting New Therapies

Amylyx Pharmaceuticals to Present at Needham Virtual Healthcare Conference Highlighting New Therapies

Amylyx Pharmaceuticals to Present at Needham Virtual Healthcare Conference Highlighting New Therapies
Trendline Trendline
Cingulate's ADHD Drug Faces FDA Manufacturing Review, No Safety Concerns Reported

Cingulate's ADHD Drug Faces FDA Manufacturing Review, No Safety Concerns Reported

Cingulate's ADHD Drug Faces FDA Manufacturing Review, No Safety Concerns Reported
Trendline Trendline
Stonegate Capital Partners Updates Coverage on Cingulate Inc. Amid Manufacturing Focus

Stonegate Capital Partners Updates Coverage on Cingulate Inc. Amid Manufacturing Focus

Stonegate Capital Partners Updates Coverage on Cingulate Inc. Amid Manufacturing Focus
Trendline Trendline
Allucent Expands Leadership to Enhance Drug Development for Biopharma

Allucent Expands Leadership to Enhance Drug Development for Biopharma

Allucent Expands Leadership to Enhance Drug Development for Biopharma
Trendline Trendline
Apnimed Secures $150 Million Financing to Support Potential U.S. Launch of Sleep Apnea Treatment

Apnimed Secures $150 Million Financing to Support Potential U.S. Launch of Sleep Apnea Treatment

Apnimed Secures $150 Million Financing to Support Potential U.S. Launch of Sleep Apnea Treatment
Trendline Trendline
Amphastar Pharmaceuticals to Present at Needham Healthcare Conference Highlighting Strategic Growth

Amphastar Pharmaceuticals to Present at Needham Healthcare Conference Highlighting Strategic Growth

Amphastar Pharmaceuticals to Present at Needham Healthcare Conference Highlighting Strategic Growth
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio

Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio

Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders
Trendline Trendline
Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline
Trendline Trendline
Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Claims Following Trial Discontinuation

Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Claims Following Trial Discontinuation

Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Claims Following Trial Discontinuation